Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 2, 2012, Pages 159-174

  Vrdoljak, Eduard ^a   Ciuleanu, Tudor ^b   Kharkevich, Galina ^c   Mardiak, Jozef ^d   Mego, Michal ^e   Padrik, Peeter ^f   Petruželka, Luboš ^g   Purkalne, Gunta ^h   Shparyk, Yaroslav ⁱ   Škrbinc, Breda ^j   Szczylik, Cezary ^k   Torday, Laszlo ^l  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b Oncologic Institute Ion Chiricu   (Romania)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^d Bratislava   (Slovakia)

^e Faculty of Natural Sciences   (Slovakia)

^f TARTU UNIVERSITY HOSPITAL   (Estonia)

^g CHARLES UNIVERSITY   (Czech Republic)

^h PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

ⁱ Lviv Cancer Center   (Ukraine)

^j INSTITUTE OF ONCOLOGY   (Slovenia)

^k MILITARY INSTITUTE OF MEDICINE   (Poland)

^l UNIVERSITY OF SZEGED   (Hungary)

more..

Author keywords

Bevacizumab; Cytokines; Everolimus; Metastatic renal cell carcinoma; Molecular targeted agents; Pazopanib; Receptor tyrosine kinase inhibitors; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VINBLASTINE;

ANEMIA; ANOREXIA; BLEEDING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; EMBOLISM; EUROPE; FATIGUE; HAND SKIN FOOT REACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERCREATININEMIA; HYPERGLYCEMIA; HYPERLIPASEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INFECTION; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; METABOLIC DISORDER; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OBESITY; PATIENT CARE; PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; PROTEINURIA; RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN TOXICITY; SMOKING; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COSTS AND COST ANALYSIS; EUROPE; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; RISK FACTORS;

EID: 84855904132     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.647406     Document Type: Review

References (52)

1. Ferlay J, Shin HR, Bray F, et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. GLOBOCAN 2008. Available from: http://globocan.iarc.fr [Last accessed 28 January 2011]
2. Coleman MP, Gatta G, Verdecchia A, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003;14 (Suppl 5):v128-49
3. Cancer Facts & Figures. MEPs Against Cancer, 2011. Available from: http://www.mepsagainstcancer.org/index.php? option=com-frontpage&Itemid=1 [Last accessed 16 August 2011]
4. Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 (Suppl 5):v137-9
5. Hsu CC, Chow WH, Boffetta P, et al. Dietary risk factors for kidney cancer in eastern and central Europe. Am J Epidemiol 2007;166(1):62-70 (Pubitemid 47234290)
6. Plesko I, Obsitnikova A, Cuninkova M, et al. Increasing occurrence of urological cancers in Slovakia. Neoplasma 2004;51(4):248-54 (Pubitemid 38915540)
7. World Economic Outlook Database. International Monetary Fund
8. Dusek L, Muzik J, Gelnarova E, et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2010;23(5):311-24
9. Epidemiology of Malignant Tumors in the Czech Republic. Available from: http://www.svod.cz
10. Onkoloski Institut Ljubljana. Available from: http://www.onko-i.si/ dejavnosti/epidemiologija-in-register-raka/registri-raka/register-raka-rs/index. html
11. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Lyon, France: International Agency for Research on Cancer; 2004
12. Hunt JD, van der Hel OL, McMillan GP, et al. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 2005;114(1):101-8 (Pubitemid 40194314)
13. WHO Global Infobase. World Health Organization, 2011. Available from: http://www.imf.org/external/pubs/ft/weo/2010/02/weodata/index.aspx [Last accessed 12 February 2011]
14. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4(8):579-91 (Pubitemid 39025053)
15. Adams KF, Leitzmann MF, Albanes D, et al. Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol 2008;168(3):268-77 (Pubitemid 352019778)
16. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005;23(21):4742-54 (Pubitemid 46224078)
17. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006;118(3):728-38 (Pubitemid 43076024)
18. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335(7630):1134
19. Bergstrom A, Hsieh CC, Lindblad P, et al. Obesity and renal cell cancer- a quantitative review. Br J Cancer 2001;85(7):984-90 (Pubitemid 33016001)
20. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. World Cancer Research Fund, American Institute for Cancer Research. American Institute for Cancer Research; Washington, DC: 2007
21. Mahabir S, Leitzmann MF, Pietinen P, et al. Physical activity and renal cell cancer risk in a cohort of male smokers. Int J Cancer 2004;108(4):600-5 (Pubitemid 38036663)
22. Moore SC, Chow WH, Schatzkin A, et al. Physical activity during adulthood and adolescence in relation to renal cell cancer. Am J Epidemiol 2008;168(2):149-57 (Pubitemid 351951591)
23. van Dijk BA, Schouten LJ, Kiemeney LA, et al. Relation of height, body mass, energy intake, and physical activity to risk of renal cell carcinoma: results from the Netherlands Cohort Study. Am J Epidemiol 2004;160(12):1159-67 (Pubitemid 39628056)
24. Lee JE, Mannisto S, Spiegelman D, et al. Intakes of fruit, vegetables, and carotenoids and renal cell cancer risk: a pooled analysis of 13 prospective studies. Cancer Epidemiol Biomarkers Prev 2009;18(6):1730-9
25. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13(3):688-96
26. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353:14-17
27. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17(9):2859-67 (Pubitemid 29415245)
28. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007;57(2):112-25 (Pubitemid 46535711)
29. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96 (Pubitemid 34032623)
30. Mekhail TM, bou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23(4):832-41 (Pubitemid 46224183)
31. Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002;13(9):1460-8
32. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24 (Pubitemid 46089672)
33. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
34. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28(13):2144-50
35. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11 (Pubitemid 350296300)
36. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
37. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81 (Pubitemid 46849157)
38. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34 (Pubitemid 46089673)
39. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(8):1280-9
40. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
41. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
42. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137-43
43. Di LG, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59(4):526-40
44. Rini BI, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. J Clin Oncol 2011;29(Suppl):abstract 4503
45. National Cancer Institute. National Cancer Institute 2011. Available from: http://www.cancer.gov/clinicaltrials
46. Hellenthal NJ, Underwood W, Penetrante R, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010;184(3):859-64
47. Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. The role of molecular markers in the staging of renal cell carcinoma. BJU Int 2007;99(5 Pt B):1208-11 (Pubitemid 46624161)
48. NCCN clinical practice guidelines in oncology: kidney cancer. Verson I.2012. National Comprehensive Cancer Network, Inc. 2011. Available from: http://www.nccn. org/professionals/physician-gls/pdf/kidney.pdf
49. IMS Sutent Summary. Pfizer data on file
50. World Health Statistics. Global Health Observatory. WHO, 2011. Available from: http://apps.who.int/ghodata/[Last accessed 12 February 2011]
51. Remak E, Charbonneau C, Negrier S, et al. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008;26(24):3995-4000
52. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146(4):473-81